These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Martinez Del Pero M; Chaudhry A; Jones RB; Sivasothy P; Jani P; Jayne D Clin Otolaryngol; 2009 Aug; 34(4):328-35. PubMed ID: 19673980 [TBL] [Abstract][Full Text] [Related]
8. Rituximab (MABTHERA) and severe polyangiitis. An option for patients informed of the uncertainties. Prescrire Int; 2015 Jun; 24(161):145-8. PubMed ID: 26436161 [TBL] [Abstract][Full Text] [Related]
9. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. Pagnoux C; Mahr A; Hamidou MA; Boffa JJ; Ruivard M; Ducroix JP; Kyndt X; Lifermann F; Papo T; Lambert M; Le Noach J; Khellaf M; Merrien D; Puéchal X; Vinzio S; Cohen P; Mouthon L; Cordier JF; Guillevin L; N Engl J Med; 2008 Dec; 359(26):2790-803. PubMed ID: 19109574 [TBL] [Abstract][Full Text] [Related]
10. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Keogh KA; Wylam ME; Stone JH; Specks U Arthritis Rheum; 2005 Jan; 52(1):262-8. PubMed ID: 15641078 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617 [TBL] [Abstract][Full Text] [Related]
12. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis]. Roccatello D; Vangelista A; Pani A G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261 [TBL] [Abstract][Full Text] [Related]
13. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre. Pullerits R; Ljevak M; Vikgren J; Bokarewa M Scand J Immunol; 2012 Oct; 76(4):411-20. PubMed ID: 22823472 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis. Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054 [TBL] [Abstract][Full Text] [Related]
16. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. Jayne D; Rasmussen N; Andrassy K; Bacon P; Tervaert JW; Dadoniené J; Ekstrand A; Gaskin G; Gregorini G; de Groot K; Gross W; Hagen EC; Mirapeix E; Pettersson E; Siegert C; Sinico A; Tesar V; Westman K; Pusey C; N Engl J Med; 2003 Jul; 349(1):36-44. PubMed ID: 12840090 [TBL] [Abstract][Full Text] [Related]
17. Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Ezeonyeji AN; Isenberg DA Rheumatology (Oxford); 2012 Mar; 51(3):476-81. PubMed ID: 22096015 [TBL] [Abstract][Full Text] [Related]